NASDAQ:NBIX - Neurocrine Biosciences News Headlines

$83.92
-0.16 (-0.19 %)
(As of 06/16/2019 10:31 AM ET)
Today's Range
$82.77
Now: $83.92
$84.52
50-Day Range
$72.24
MA: $79.81
$84.78
52-Week Range
$64.72
Now: $83.92
$126.98
Volume509,256 shs
Average Volume645,076 shs
Market Capitalization$7.66 billion
P/E Ratio381.45
Dividend YieldN/A
Beta1.46

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:
DateHeadline
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Quarterly Sales of $165.23 MillionNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Quarterly Sales of $165.23 Million
www.americanbankingnews.com - June 13 at 5:30 AM
Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)
finance.yahoo.com - June 11 at 6:51 PM
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinsons Disease and Related DisordersNeurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
finance.yahoo.com - June 11 at 6:51 PM
 Brokerages Expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Will Post Earnings of $0.27 Per Share Brokerages Expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Will Post Earnings of $0.27 Per Share
www.americanbankingnews.com - June 11 at 2:14 AM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $293,726.85 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $293,726.85 in Stock
www.americanbankingnews.com - June 5 at 8:39 PM
Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare ConferenceNeurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
finance.yahoo.com - June 4 at 6:29 PM
Neurocrine Biosciences (NBIX) Research Coverage Started at GuggenheimNeurocrine Biosciences (NBIX) Research Coverage Started at Guggenheim
www.americanbankingnews.com - June 4 at 6:27 PM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $1,640,630.94 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $1,640,630.94 in Stock
www.americanbankingnews.com - June 3 at 8:19 PM
First Week of July 19th Options Trading For Neurocrine Biosciences (NBIX)First Week of July 19th Options Trading For Neurocrine Biosciences (NBIX)
www.nasdaq.com - June 3 at 6:32 PM
Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount?Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount?
finance.yahoo.com - May 31 at 6:34 PM
Traders Purchase Large Volume of Call Options on Neurocrine Biosciences (NBIX)Traders Purchase Large Volume of Call Options on Neurocrine Biosciences (NBIX)
www.americanbankingnews.com - May 31 at 8:09 AM
Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare ConferenceNeurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
finance.yahoo.com - May 30 at 6:21 PM
Neurocrine Biosciences, Inc. (NBIX) Given Consensus Rating of "Buy" by AnalystsNeurocrine Biosciences, Inc. (NBIX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 3:23 AM
Haig P. Bozigian Sells 17,486 Shares of Neurocrine Biosciences, Inc. (NBIX) StockHaig P. Bozigian Sells 17,486 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
www.americanbankingnews.com - May 29 at 8:16 PM
Neurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 1,300 SharesNeurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 1,300 Shares
www.americanbankingnews.com - May 23 at 8:32 PM
AbbVie Launches ORILISSA(TM) (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with EndometriosisAbbVie Launches ORILISSA(TM) (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis
www.marketwatch.com - May 21 at 11:20 AM
AbbVie launches higher dose OrilissaAbbVie launches higher dose Orilissa
seekingalpha.com - May 21 at 11:20 AM
AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with EndometriosisAbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis
finance.yahoo.com - May 21 at 11:20 AM
Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of LifeNeurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
finance.yahoo.com - May 20 at 9:28 AM
Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual MeetingNeurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
finance.yahoo.com - May 16 at 7:26 PM
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019
finance.yahoo.com - May 7 at 6:40 PM
Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on PatientsNeurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
www.marketwatch.com - May 6 at 8:48 AM
Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinsons Disease Patients with Motor FluctuationsNeurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations
www.prnewswire.com - May 5 at 9:34 AM
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinsons Disease at the American Academy of Neurology Annual MeetingNeurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
www.prnewswire.com - May 5 at 9:34 AM
Neurocrine Drifting, But The Total Package Is Still AppealingNeurocrine Drifting, But The Total Package Is Still Appealing
seekingalpha.com - April 30 at 6:33 PM
Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual MeetingNeurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 30 at 6:33 PM
Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMTEdited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT
finance.yahoo.com - April 30 at 8:41 AM
Neurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call TranscriptNeurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call Transcript
www.fool.com - April 30 at 12:10 AM
First Week of NBIX June 21st Options TradingFirst Week of NBIX June 21st Options Trading
www.nasdaq.com - April 29 at 6:25 PM
Neurocrine Biosciences Reports First Quarter 2019 Financial ResultsNeurocrine Biosciences Reports First Quarter 2019 Financial Results
www.marketwatch.com - April 29 at 6:25 PM
Neurocrine Biosciences Q1 2019 Earnings PreviewNeurocrine Biosciences Q1 2019 Earnings Preview
seekingalpha.com - April 29 at 8:38 AM
Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ?Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ?
finance.yahoo.com - April 21 at 8:50 AM
Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company?Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company?
finance.yahoo.com - April 16 at 7:21 PM
United States : Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial ResultsUnited States : Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
www.marketwatch.com - April 10 at 7:58 PM
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial ResultsNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
finance.yahoo.com - April 8 at 7:28 PM
Analysts Raise Neurocrine Biosciences’ Target Price in MarchAnalysts Raise Neurocrine Biosciences’ Target Price in March
finance.yahoo.com - March 29 at 7:11 PM
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of NeurologyNeurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
finance.yahoo.com - March 28 at 7:03 PM
Noteworthy Thursday Option Activity: NBIX, CRUS, CNoteworthy Thursday Option Activity: NBIX, CRUS, C
www.nasdaq.com - March 21 at 7:18 PM
Neurocrine Biosciences: Rapid Pipeline Expansion UnderwayNeurocrine Biosciences: Rapid Pipeline Expansion Underway
seekingalpha.com - March 19 at 7:14 PM
Neurocrine Biosciences May Have Something Interesting With NBI-74788Neurocrine Biosciences May Have Something Interesting With NBI-74788
seekingalpha.com - March 13 at 6:48 PM
Neurocrine Bios NBI-74788 shows positive action in mid-stage adrenal hyperplasia studyNeurocrine Bio's NBI-74788 shows positive action in mid-stage adrenal hyperplasia study
seekingalpha.com - March 12 at 9:12 AM
Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal HyperplasiaNeurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia
finance.yahoo.com - March 12 at 9:12 AM
Why These 2 Biotech Stocks Might Be Next On The Takeover ListWhy These 2 Biotech Stocks Might Be Next On The Takeover List
finance.yahoo.com - March 1 at 6:39 PM
Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Is An Attractive Investment To ConsiderWhy Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Is An Attractive Investment To Consider
finance.yahoo.com - February 28 at 6:42 PM
Neurocrine Dives Into Gene TherapyNeurocrine Dives Into Gene Therapy
seekingalpha.com - February 27 at 6:57 PM
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
www.zacks.com - February 12 at 8:46 AM
Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMTEdited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT
finance.yahoo.com - February 7 at 8:45 AM
Neurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call TranscriptNeurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript
www.fool.com - February 5 at 9:49 PM
Neurocrine Bio Q4 Ingrezza sales up 102%; earnings up 162%Neurocrine Bio Q4 Ingrezza sales up 102%; earnings up 162%
seekingalpha.com - February 5 at 6:07 PM
Neurocrine Biosciences (NBIX) Beats Q4 Earnings EstimatesNeurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates
www.zacks.com - February 5 at 6:07 PM
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Featured Article: What are retained earnings?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel